Elagolix - Abbvie/Neurocrine Biosciences

Drug Profile

Elagolix - Abbvie/Neurocrine Biosciences

Alternative Names: ABT-620; Elagolix sodium; NBI-56418; ORILISSA

Latest Information Update: 23 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Icahn School of Medicine at Mount Sinai
  • Developer AbbVie; Neurocrine Biosciences
  • Class Antineoplastics; Fluorinated hydrocarbons; Pyrimidines; Small molecules
  • Mechanism of Action LHRH receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Endometriosis
  • Phase III Uterine leiomyoma
  • Discontinued Benign prostatic hyperplasia; Prostate cancer

Most Recent Events

  • 08 Oct 2018 AbbVie terminates a phase III trial for Endometriosis (Combination therapy) in the US due to strategic considerations (NCT03343067)
  • 05 Oct 2018 Registered for Endometriosis in Canada (PO)
  • 05 Oct 2018 AbbVie plans to launch elagolix in Canada in November 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top